- $6.22bn
- $5.29bn
- $621.15m
- 76
- 18
- 57
- 49
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 46.5 | 93.1 | 205 | 422 | 621 |
Cost of Revenue | |||||
Gross Profit | 28.1 | 53.7 | 123 | 278 | 442 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 121 | 209 | 472 | 825 | 1,000 |
Operating Profit | -75 | -116 | -267 | -403 | -378 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -76.3 | -117 | -270 | -384 | -333 |
Provision for Income Taxes | |||||
Net Income After Taxes | -76.6 | -118 | -271 | -379 | -339 |
Net Income Before Extraordinary Items | |||||
Net Income | -76.6 | -118 | -271 | -379 | -339 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -76.6 | -118 | -271 | -379 | -339 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.299 | -0.459 | -0.999 | -1.31 | -1.1 |
Dividends per Share |